Effect of serelaxin on mode of death in acute heart failure: Results from the RELAX-AHF study

Journal of the American College of Cardiology

Volumn 64, Issue 15, 2014, Pages 1591-1598

  Felker, G Michael ^a   Teerlink, John R ^b   Butler, Javed ^c   Hernandez, Adrian F ^a   Miller, Alan B ^d   Cotter, Gad ^e   Davison, Beth A ^e   Filippatos, Gerasimos ^f   Greenberg, Barry H ^g   Ponikowski, Piotr ^h   Voors, Adriaan A ⁱ   Hua, Tsushung A ^j   Severin, Thomas M ^j   Unemori, Elaine ^k   Metra, Marco ^l  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e Momentum Research Inc   (United States)

^f NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁱ Ek   (Netherlands)

^j NOVARTIS PHARMA AG   (Switzerland)

^k Novartis Pharma AG ^*  (United States)

^l UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

cause of death; heart failure; relaxin; sudden cardiac death

Indexed keywords

PLACEBO; SERELAXIN; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; ACUTE DISEASE; AGED; CLINICAL TRIAL; COMPLICATION; DEATH, SUDDEN, CARDIAC; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ACUTE DISEASE; AGED; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RELAXIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84908130787     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.05.071     Document Type: Article

References (21)

1. A.S. Go, D. Mozaffarian, and V.L. Roger Heart disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 2013 e6 e245
2. M.S. Nieminen, M. Bohm, and M.R. Cowie Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 384 416
3. J.R. Teerlink, G. Cotter, and B.A. Davison Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
4. C.M. O'Connor, R.C. Starling, and A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
5. M.A. Konstam, M. Gheorghiade, and J.C. Burnett Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331
6. M.R. Zile, W.H. Gaasch, and I.S. Anand Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial Circulation 121 2010 1393 1405
7. P. Carson, J. Wertheimer, and A. Miller The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results J Am Coll Cardiol HF 1 2013 400 408
8. C.M. O'Connor, A.B. Miller, and J.E. Blair Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) program Am Heart J 159 2010 841 849.e1
9. ClinicalTrials.gov. Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF). Available at: http://clinicaltrials.gov/show/NCT00520806. Accessed August 4, 2014.
10. P. Ponikowski, M. Metra, and J.R. Teerlink Design of the RELAXin in acute heart failure study Am Heart J 163 2012 149 155.e1
11. M. Metra, G. Cotter, and B.A. Davison Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes J Am Coll Cardiol 61 2013 196 206
12. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
13. L.J. Wei, D.Y. Lin, and L. Wiessfeld Regression analysis of multivariate incomplete failure time data by modeling marginal distributions J Am Stat Assoc 84 1989 1065 1073
14. M. Gheorghiade, W.T. Abraham, and N.M. Albert Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2006 2217 2226
15. G.C. Fonarow, K.F. Adams Jr., and W.T. Abraham Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis JAMA 293 2005 572 580
16. S.L. Teichman, E. Unemori, and T. Dschietzig Relaxin, a pleiotropic vasodilator for the treatment of heart failure Heart Fail Rev 14 2009 321 329
17. J.L. Januzzi, G. Filippatos, and M. Nieminen Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section Eur Heart J 33 2012 2265 2271
18. B.F. Uretsky, K. Thygesen, and P.W. Armstrong Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment With Lisinopril and Survival (ATLAS) trial Circulation 102 2000 611 616
19. S. Orn, J.G.F. Cleland, and M. Romo Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Am J Med 118 2005 752 758
20. H.A. Cooper, D.L. Dries, and C.E. Davis Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction Circulation 100 1999 1311 1315
21. 1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT Drug Saf 35 2012 233 244